Emerald Advisers’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Emerald Advisers’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-15,418	Closed	-$2.24M	–	340
2015 Q3	$2.24M	Sell	15,418 -4,481	-23%	-$822K	0.12%	201
2015 Q2	$4.23M	Buy	19,899 +101	+0.5%	+$24.8K	0.2%	141
2015 Q1	$4.97M	Sell	19,798 -22	-0.1%	-$5.32K	0.25%	129
2014 Q4	$4.57M	Buy	+19,820	New	+$4.25M	0.24%	131

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Emerald Advisers's BLCM Position: Q4 2015 in Review

Emerald Advisers sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2015, closing a stake of 15,418 shares — an estimated $2.24M sold.

Emerald Advisers first reported a position in BLCM in Q4 2014 and held it in 4 quarters. The position peaked at $4.97M in Q1 2015. 81 funds tracked by Wall St. Rank hold BLCM as of Q4 2015.

Emerald Advisers reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
Emerald Advisers sold 15,418 Bellicum Pharmaceuticals, Inc. shares in Q4 2015, an estimated $2.24M.
Emerald Advisers first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 4 quarters.
Emerald Advisers's Bellicum Pharmaceuticals, Inc. position peaked at $4.97M in Q1 2015.
81 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2015.

Based on Emerald Advisers's 13F filing for Q4 2015, filed 25 Jan 2016.